Chemistry:Samatasvir

From HandWiki
Short description: Chemical compound
Samatasvir
Samatasvir.svg
Clinical data
Routes of
administration
Oral
Legal status
Legal status
  • Investigational
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
Chemical and physical data
FormulaC47H48N8O6S2
Molar mass885.07 g·mol−1
3D model (JSmol)

Samatasvir (IDX-719) is an experimental drug for the treatment of hepatitis C. It was originally developed by Idenix, and development has been continued by Merck & Co. following their acquisition of Idenix. Samatasvir has shown good results in Phase II trials.[1]

Samatasvir is a highly potent and selective inhibitor of the hepatitis C virus NS5A replication complex.[2] While it showed promising results when administered as monotherapy, it is probable that samatasvir would be marketed as a combination product with other anti-hepatitis drugs to increase efficacy and reduce the chance of resistance developing, as with most other novel treatments for hepatitis C currently under development. Trials of samatasvir in combination with other antiviral drugs such as simeprevir are also underway.[3]

See also

  • Discovery and development of NS5A inhibitors

References

  1. "A randomized, double-blind, multiple-dose study of the pan-genotypic NS5A inhibitor samatasvir in patients infected with hepatitis C virus genotype 1, 2, 3 or 4". Journal of Hepatology 60 (5): 920–7. May 2014. doi:10.1016/j.jhep.2014.01.003. PMID 24434503. 
  2. "In vitro activity and resistance profile of samatasvir, a novel NS5A replication inhibitor of hepatitis C virus". Antimicrobial Agents and Chemotherapy 58 (8): 4431–42. August 2014. doi:10.1128/AAC.02777-13. PMID 24867983. 
  3. Clinical trial number NCT01852604 for "Samatasvir (IDX719) in Combinations With Simeprevir and/or TMC647055/Ritonavir With or Without Ribavirin for 12 Weeks in Participants With Chronic Hepatitis C Infection (MK-1894-005)" at ClinicalTrials.gov